Shield Therapeutics takes bold approach in the US

0
24
  • Shield Therapeutics pleased with progress to date on US launch of Accrufer
  • Shield Therapeutics’ present drive for US launch success of iron deficiency product Accrufer
Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC

Follow

View company profile

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

17 Aug 2021

(, ) () said in its half-year results that the focus in the second half will be on the roll-out of its iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

During the second quarter of 2021, the company built up a sales force and started to contact key prescribers. Due to the ongoing impact of the COVID pandemic and the emergence of the delta variant in the US, face-to-face contact with clinicians has been limited in the initial phase of launch but discussions are taking place with payers regarding formulary placement of Accrufer and will continue over the next several months.

The focus in the US will be on building awareness among healthcare providers, initiating prescriptions for appropriate patients to generate clinical experience and extending patient access through negotiations with payer groups.

Read more

12 Aug 2021

(, ) shares surged on Thursday as it said it has secured a licence agreement in South Korea for its Accrufer iron deficiency therapy.

Under the deal with Korea Pharma Co Ltd, the company said it will receive an upfront payment of GBP0.5mln and is also eligible to receive a further GBP1.5mln upon the first commercial sale of Accrufer in Korea.

Read more

09 Aug 2021

(, ) () has flagged up research in a leading academic publication showcasing some “very exciting” results from a study involving its lead product.

Investigators assessed the potential of Feraccru (known as Accrufer in the US, and also called ferric maltol).

Read more

17 Aug 2021

(, ) () new CEO Greg Madison talks to Proactive London about his strategy for the company and focus on driving the iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

During the second quarter of 2021, the company built up a sales force and started to contact key prescribers. Due to the ongoing impact of the COVID pandemic and the emergence of the delta variant in the US, face-to-face contact with clinicians has been limited in the initial phase of launch but discussions are taking place with payers regarding formulary placement of Accrufer and will continue over the next several months.

11 Mar 2021

STX is preparing to launch prescription iron replacement treatment Accrufer in the US, a market estimated to be worth US$1.2bn pa, the largest global market for iron replacement treatment. A self-launch can provide STX with the lion’s share of projected profits, peak sales estimate of up to US$400mln by year six, and is timely given the opportunity to gain traction given the unmet need for a well-tolerated, effective and convenient treatment for Iron Deficiency (ID). STX estimates that funding of US$40mln (GBP29mln) will enable it to rapidly ramp up revenues, sufficient to reach break-even at the 18-month point. The projected strategy, 90% margin product profile and promising conclusions from market research with top ten US payers suggest the potential for significant cash generation. The US launch on its own, if executed in line with STX’s internal projections, can more than justify the market capitalisation of the company, even applying conservative projections.

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics’ present drive for US launch success of iron deficiency…

Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LSE:STX) new CEO Greg Madison talks to Proactive London about his strategy for the company and focus on driving the iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s…

18 hours, 25 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here